Prostate cancer prevention: Concepts and clinical trials

Current Urology Reports

Volumn 17, Issue 4, 2016, Pages

  Hamilton, Zachary ^a   Parsons, J Kellogg ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

5 Alpha reductase inhibitors; Immunotherapy; Prostate cancer

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BICALUTAMIDE; DUTASTERIDE; FINASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; RILIMOGENE GALVACIREPVEC; SELENIUM; STEROID 5ALPHA REDUCTASE INHIBITOR;

ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; DIET THERAPY; DRUG EFFICACY; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; TERTIARY PREVENTION; CLINICAL TRIAL (TOPIC); DIET; DISEASE COURSE; MALE; PROSTATIC NEOPLASMS; RECURRENT DISEASE; RISK FACTOR;

CLINICAL TRIALS AS TOPIC; DIET; DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC NEOPLASMS; RECURRENCE; RISK FACTORS;

EID: 85003952960     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-016-0587-1     Document Type: Article

References (60)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5-29.
2. Tao ZQ, Shi AM, Wang KX, ZhangWD. Epidemiology of prostate cancer: current status. Eur Rev Med Pharmacol Sci. 2015;19(5): 805-12.
3. Punnen S, Cooperberg MR. The epidemiology of high-risk prostate cancer. Curr Opin Urol. 2013;23:331-6.
4. Moyer VA. U.S. Preventive Services Task Force. screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-34.
5. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8.
6. Silberstein JL, Parsons JK. Prostate cancer prevention: concepts and clinical recommendations. Prostate Cancer Prostatic Dis. 2010;13(4):300-6.
7. Yamaguchi K, Uzzo RG, Pimkina J, Makhov P, Golovine K, Crispen P, et al. Methylseleninic acid sensitizes prostate cancer cells to TRAIL-mediated apoptosis. Oncogene. 2005;24:5868-77.
8. Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, et al. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA). Prostate. 2006;66:1070-5.
9. van den Brandt PA, Zeegers MPA, Bode P, Goldbohm RA. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2003;12:866-71.
10. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003;91:608-12.
11. Chan JM, Stampfer MJ, Ma J, Rimm EB, WillettWC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev. 1999;8:893-9.
12. Kirsh VA, Hayes RB, Mayne ST, Chatterjee N, Subar AF, Dixon LB, et al. Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk. J Natl Cancer Inst. 2006;98:245-54.
13. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39-51. This was a phase III trial with over 35,000 men examining natural substances (selenium and vitamin E) for chemoprevention of prostate cancer. After 7 years of follow up, no significant benefit was seen for either substance.With additional follow up, there was a small but significantly increased risk of prostate cancer in the vitamin E group.
14. Klein EA, Thompson Jr IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549-56.
15. Stevens VL, McCullough ML, Diver WR, et al. Use of multivitamins and prostate cancer mortality in a large cohort of US men. Cancer Causes Control. 2005;16(6):643-50.
16. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2009;301:52-62.
17. Thomas LN, Douglas RC, Lazier CB, Too CK, Rittmaster RS, Tindall DJ. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol. 2008;53: 244-52.
18. Rittmaster RS, Manning AP, Wright AS, Thomas LN, Whitefield S, Norman RW, et al. Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endocrinology. 1995;136:741-8.
19. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. NEngl JMed. 2003;349:215-24. This was a phase III trial evaluating the use of finasteride for prevention of prostate cancer over a 7 year follow up period. Over 18,000 men (at least 55 years old, PSA≤ 3 ng/ml, normal DRE) were enrolled with for-cause biopsy or end-of-study biopsy performed. There was a 25% relative risk reduction in prostate cancer detection associated with finasteride, although higher grade disease was diagnosed more frequently in the finasteride cohort.
20. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99: 1375-83.
21. Mellon JK. The finasteride Prostate Cancer Prevention Trial (PCPT)-what have we learned? Eur J Cancer. 2005;41:2016-22.
22. Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2007;10:149-54.
23. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192-202. This was a phase III trial evaluating the use of dutasteride for prevention of prostate cancer over a 4 year period. 8000 men (50-75 years old, PSA 2.5-10 ng/ml, negative prostate biopsy within 6 months of enrollment) were screened every 6 months with for-cause biopsy or planned biopsy at 2 and 4 years performed. There was a 23 % relative risk reduction associated with dutasteride and an increased incidence of high grade disease in the dutasteride cohort. This confirmed the findings of the PCPT trial.
24. Lacy JM, Kyprianou N. A tale of two trials: the impact of 5α-reductase inhibition on prostate cancer (review). Oncol Lett. 2014;8(4):1391-6.
25. Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R. The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011;365(2):97-9.
26. Kim J, Amos CI, Logothetis C. 5α-Reductase inhibitors for prostate-cancer prevention. N Engl J Med. 2011;365(24):2340.
27. Welch HG, Gorski DH, Albertsen PC. Trends in metastatic breast and prostate cancer-lessons in cancer dynamics. N Engl J Med. 2015;373(18):1685-7.
28. Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol. 1999;17:3167-72.
29. Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012;118(23):5955-63.
30. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
31. Carroll PR, Parsons JK, Andriole G, et al. Prostate cancer early detection, version 1.2014. featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014;12(9):1211-9. quiz 1219.
32. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-34.
33. Penson DF. The pendulum of prostate cancer screening. JAMA. 2015;314(19):2031-3.
34. Schröder FH, Hugosson J, Roobol MJ. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027-35.
35. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Onc. 2010;11:725-32.
36. Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125-32.
37. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310-9.
38. Grubb RL, Pinsky PF, Greenlee RT, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008;102(11):1524-30.
39. Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, doubleblind, placebo-controlled trial. Lancet. 2012;379:1103-11. This phase III trial evaluated the use of dutasteride in an active surveillance cohort, enrolling 302 men with low risk prostate cancer and following them over a 3 year period with planned biopsies performed at 1.5 and 3 years. There was a 38 % relative risk reduction in pathologic and therapeutic progression in the dutasteride cohort, although it was unclear if this was due to a true medication effect or instead due to reductions in patient/ provider treatment anxiety given that dutasteride lowers PSA values and improves PSA operating characteristics.
40. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98:1128-33.
41. Latini DM, Hart SL, Knight SJ, et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007;178(3 Pt 1):826-31. discussion 831-2.
42. Schröder F, Bangma C, Angulo JC, et al. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS). Eur Urol. 2013;63(5): 779-87.
43. Ehdaie B, Touijer KA. 5-alpha Reductase inhibitors in prostate cancer: from clinical trials to clinical practice. Eur Urol. 2013;63(5):788-9. discussion 790-1.
44. Parsons JK, Pierce JP, Mohler J, et al. A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men’s Eating and Living (MEAL) Study. Contemp Clin Trials. 2014;38(2):198-203.
45. Geary SM, Salem AK. Prostate cancer vaccines: update on clinical development. Oncoimmunology. 2013;2(5):e24523.
46. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670-9.
47. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22.
48. Gulley JL, Heery CR, Madan RA, et al. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunol Immunother. 2013;62(9):1521-31.
49. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099-105.
50. Sartor O, Gomella LG, Gagnier P, Melich K, Dann R. Dutasteride and bicalutamide in patients with hormonerefractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design. Can J Urol. 2009;16(5):4806-12.
51. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11:1-160.
52. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol, Biomarkers Prevent: Public Am Assoc Cancer Res, Cosponsored Am Soc Prevent Oncol. 2008;17:88-94.
53. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115: 959-68.
54. Bansal D, Undela K, D’Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One. 2012;7:e46691.
55. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a populationbased epidemiologic study. Am J Epidemiol. 2008;168:250-60.
56. Platz EA, Tangen CM, Goodman PJ, et al. Statin drug use is not associated with prostate cancer risk in men who are regular screened. Urology. 2014;192(2):379-84.
57. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol. 2004;172:S6-11. discussion S11-12.
58. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366-81.
59. Choe KS, Cowan JE, Chan JM, Carroll PR, D’Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012;30: 3540-4.
60. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, et al. A large cohort study of aspirin and other nonsteroidal antiinflammatory drugs and prostate cancer incidence. J Natl Cancer Inst. 2005;97:975-80.